Curtis Berlinguette reports articles, exploitinge Cold Fusion experiments (Hydrogen in metal), in non LENR applications, as Pharmacy.
Electrolytic deuteration of unsaturated bonds without using D2
Site-selective deuteration of C–H bonds increases the lifetime and efficacy of drug molecules. Although effective methods to form C(sp2)–D bonds are known, processes for making C(sp3)–D bonds often have low site selectivity, require expensive and unrecoverable D2 gas, or use stoichiometric reagents. Here we report cost-efficient and site-selective reductive deuteration using a tandem electrochemical chemical palladium membrane reactor. This architecture mediates the chemical reaction of deuterium atoms (derived from reusable D2O in an electrochemical compartment) with alkynes, aldehydes and imines. The formation of C(sp3)–D and C(sp2)–D bonds in the isolated chemical compartment is made possible by the deuterium-selective permeability of the membrane that partitions the electrochemical compartment from the chemical compartment. We have utilized the reactor for the deuteration step in the construction of a common drug, cinacalcet, to demonstrate that this method can be used to incorporate deuterium atoms in a pharmaceutical.
From cold fusion to pharmaceuticals
Revisiting "cold fusion" led us to discover the electrolytic hydrogenation/deuteration reactor that is electrically-driven and uses water as a hydrogen/deuterium source. This technology opens new avenues for using renewable energy to make valuable chemicals, including pharmaceuticals.
Discussed here Google (UBC/MIT/LBNL) post Nature updates.